 |
 |
| February 25, 2010 |
StromaCel |
 |
Proteonomix, Inc. (PROT) Announces the Appointment of Ashoke Agarwal, M.D. as Chief Scientific Officer of Its Subsidiary, StromaCel, Inc. |
 |
MOUNTAINSIDE, NJ - Proteonomix, Inc. (PINKSHEETS: PROT) announces the appointment of Ashoke Agarwal, M.D., F.A.C.C. as Chief Scientific Officer of its subsidiary, StromaCel, Inc. Dr. Agarwal, 62 years old, is also Chief Scientific Officer for the Company's subsidiary, National Stem Cell, Inc. He has been in private practice in the fields of Internal Medicine and Cardiology since 1983 and is affiliated with four hospitals in New Jersey... |
|
| Read Full Story > |
|
 |
| February 18, 2010 |
SromalCel |
|
Proteonomix, Inc. (PROT) Announces the Formation of StromaCel, Inc. |
|
MOUNTAINSIDE, NJ - Proteonomix, Inc. (PINKSHEETS: PROT) announces that it has formed a wholly-owned subsidiary, StromaCel, Inc. The mission of StromaCel is to develop therapies using StromaCels. StromaCels are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells... |
|
| Read Full Story > |
|
 |
| February 12, 2010 |
PRTMI |
|
Proteonomix, Inc. (PROT) Announces the Formation of Proteonomix Regenerative Translational Medicine Institute, Inc. |
|
MOUNTAINSIDE, NJ - Proteonomix, Inc. (PINKSHEETS: PROT) announces that it has formed a wholly-owned subsidiary, Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI"). PRTMI will focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. The mission of PRTMI is to undertake preclinical and clinical trials in regenerative medicine for delivery of cutting edge therapies overcoming delays caused by non-clinical considerations. |
|
| Read Full Story > |
|
 |
| February 02, 2010 |
Proteonomix, Inc. |
|
Proteonomix, Inc. Files SEC form 8-K, Other Events EDGAR Online |
|
Proteonomix, Inc. Files SEC form 8-K, Other Events EDGAR Online |
|
| Read Full Story > |
|
 |
| February 01, 2010 |
Proteonomix, Inc. |
|
Ian McNiece, PhD, Vice President, Scientific Development, of Proteonomix, Inc. (PROT) Has Been Appointed to the Board of Directors of The Foundation for the Accreditation of Cellular Therapy (FACT) Marketwire. |
|
MISSING LINK |
|
| Read Full Story > |
|
